Ceapro Inc. Announces Publication of Results for PGX-Processed Alginates in the Journal of CO2 Utilization May 11, 2022
Ceapro Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights April 13, 2022
Ceapro Signs Exclusive Long-Term Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise March 10, 2022
Ceapro Bolsters Board of Directors with Appointment of Top Executive from Global Pharmaceutical Industry March 2, 2022
Ceapro Inc. Reports 2021 Third Quarter and Nine-Month Financial Results and Operational Highlights November 17, 2021
Ceapro Inc. Reports Preliminary Results from Clinical Trial Evaluating Oat Beta Glucan in Patients with High Cholesterol Levels November 17, 2021
Ceapro Inc. Provides Update on Development of an Inhalable Therapeutic Using Yeast Beta Glucan Processed with Pressurized Gas eXpanded Technology (PGX-YBG) November 11, 2021
